Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.

ABSTRACT:

Background

Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis with limited progression-free survival and overall survival, even when treated with different combinations of chemotherapy, targeted therapies and immunotherapy. We explored in vitro and in vivo the effect of the epidermal growth factor receptor (EGFR) inhibitor, osimertinib, alone and in combination with dihydroartemisinin (DHA) in HNSCC.

Methods

The combination of osimertinib with DHA was tested in the FaDu and CAL27 HNSCC cell lines. Tumor cell proliferation assays were conducted in cultured cells and mouse xenografts. Western blotting analysis of related signal pathways was performed to investigate the molecular mechanisms of the inhibitory effect of DHA

SUBMITTER: Chaib I 

PROVIDER: S-EPMC6944621 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature